

Effects of five candidate laxatives derived from *Liriope platyphylla* on the 5-HT receptor signaling pathway in three cell types present in the transverse colon

JI EUN KIM¹, EUN KYOUNG KOH¹, SUNG HWA SONG¹, JI EUN SUNG¹,
HYUN AH LEE¹, HONG GU LEE², YOUNG WHAN CHOI³ and DAE YOUN HWANG¹

¹Department of Biomaterials Science, College of Natural Resources and Life Science/

Life and Industry Convergence Research Institute, Pusan National University, Miryang, Gyeongsangnam-do 627-706;

²Department of Animal Science and Technology, College of Animal Bioscience and Technology,

Konkuk University, Seoul 143-701; ³Department of Horticultural Bioscience, College of Natural Resources and Life Science, Pusan National University, Miryang, Gyeongsangnam-do 627-706, Republic of Korea

Received September 17, 2015; Accepted June 27, 2016

DOI: 10.3892/mmr.2016.5983

Abstract. The laxative effects of aqueous extract of *Liriope platyphylla* (AEtLP) on loperamide (Lop)-induced constipation have been reported; however, the key compounds and the mechanism underlying these effects remain unclear. Therefore, the laxative effects of five candidates derived from *L. platyphylla*: Diosgenin (DG), 5-hydroxymethylfurfural (5-HMF), adenosine (AD), hydroxypropyl cellulose (HPC) and uridine (UD) were investigated by examining the alteration of G protein α ($G\alpha$) expression, protein kinase C (PKC) phosphorylation and inositol triphosphate (IP3) concentration levels in the 5-hydroxytryptamine (5-HT; serotonin) receptor signaling pathway. Primary rat intestine smooth muscle cells (pRISMCs), intestinal epithelial cells (IEC)-18 and B35 cells were cotreated with Lop and the five compounds in order to screen the candidates. AEtLP, prucalopride (PCP) and bisacodyl (BS) served as positive controls. In pRISMCs, $G\alpha$ expression levels were recovered in the majority of candidate-treated groups, whereas PKC phosphorylation recovery was observed only in the DG, 5-HMF and AD treatment groups. In IEC-18 cells, the AD treatment group mimicked the effects of PCP on PKC phosphorylation levels, whereas the DG, 5-HMF, HPC and UD treatment groups mimicked the effects of AEtLP and BS. In B35 cells, a greater upregulation

of PKC phosphorylation levels were observed in the UD treatment group compared with the PCP and BS treatment groups, whereas DG, 5-HMF and AD treatment reduced the PKC phosphorylation levels to a greater extent than AEtLP treatment. However, effects similar to AEtLP, PCP and BS on $G\alpha$ expression levels were not detected in any treatment groups in IEC-18 and B35 cells. Furthermore, the level of IP3 was enhanced only in pRISMCs, in which all five candidates were effective, while the greatest concentration was observed in the UD treatment group. In conclusion, the results of the present study suggest that UD may be considered the compound with the greatest laxative activity, which may regulate the 5-HT receptor signaling pathway.

Introduction

Serotonin (5-hydroxytryptamine; 5-HT) is an important neurotransmitter that is expressed in the gastrointestinal tract, blood platelets and the central nervous system (CNS) (1). However, >90% of total body 5-HT is synthesized, stored and secreted in the enterochromaffin (EC) cells of the intestinal mucosa (2). Following secretion, 5-HT exerts numerous effects on the cells and tissues of the intestine, including activation or relaxation of smooth muscle, epithelial cell secretion, stimulation of sensory neurons and activation of cholinergic neurons (3-5); however, 5-HT is rapidly removed by the serotonin uptake transporter in enterocytes and neurons (6). Furthermore, the various effects of 5-HT may be mediated by 14 5-HT receptors. Of these, the important 5-HT₃ and 5-HT₄ receptors, which are G protein-coupled receptors expressed by smooth muscle cells, EC cells and myenteric plexus neurons, are considered to be the primary pharmacological targets for gastrointestinal disorder treatment (7,8). This is due to significant alterations in the 5-HT receptor signaling pathway during inflammatory bowel disease, irritable bowel syndrome, postinfectious irritable bowel syndrome and idiopathic constipation (7,9-11). Several safe and effective chemical drugs for the treatment of irritable bowel syndrome with constipation are

Correspondence to: Professor Dae Youn Hwang, Department of Biomaterials Science, College of Natural Resources and Life Science/Life and Industry Convergence Research Institute, Pusan National University, 50 Cheonghak-ri, Samnangjin-eup, Miryang, Gyeongsangnam-do 627-706, Republic of Korea
E-mail: dyhwang@pusan.ac.kr

Key words: *liriope platyphylla*, laxative, 5-hydroxymethylfurfural, hydroxypropyl cellulose, uridine, 5-hydroxytryptamine receptor signaling pathway

widely used. Agonists of the 5-HT₄ receptor, including tegaserod, cisapride and benimidazolones, have been developed to treat slow transit through the promotion of gastric emptying and alleviation of chronic constipation, whereas 5-HT₃ receptor antagonists, including alosetron and cilansetron, have been used to treat nausea, emesis and diarrhea through decreased visceral sensitivity and postprandial motility (12-14). However, investigators are seeking novel drugs originating from natural products due to the pharmacological and economical limitations of chemical drugs, including toxicity, side effects and high cost.

Various herbal plants exhibiting laxative activity have been investigated as possible novel therapeutic strategies for the treatment of constipation to circumvent the side effects of chemical drugs (15-17). Significant improvements in intestinal motility, stool number, stool water content and distal colon thickness have previously been observed in constipated animals treated with *Aloe ferox* Mill (18), *Aquilaria sinensis*/*Aquilaria crasna* (15), and *Ficus carica* (16,19). Treatment with aqueous extract of *Liriope platyphylla* (AETLP) has also been shown to effectively improve loperamide (Lop)-induced constipation in Sprague Dawley (SD) rats via increased stool and urine excretion, villus length, crypt layer, muscle thickness and lipid droplet secretion (19). This previous study provided the first evidence that the laxative effects of AETLP may be closely correlated with the muscarinic acetylcholine receptors signaling pathway (19). However, the primary components responsible for laxative activity and the underlying mechanisms remain to be elucidated.

The present study was conducted to investigate the effects of five laxative candidates [diosgenin (DG), 5-hydroxymethylfurfural (5-HMF), adenosine (AD), hydroxypropyl cellulose (HPC) and uridine (UD)] derived from *L. platyphylla* on the 5-HT receptor downstream signaling pathway in primary rat intestine smooth muscle cells (pRISMCs), intestinal epithelial cells (IEC)-18 and B35 cells. The results of the present study provide evidence that UD may be a potential candidate for 5-HT receptor signaling pathway regulation.

Materials and methods

Care and use of laboratory animals. The animal protocol used in the present study was reviewed and approved based on ethical procedures and scientific care by the Pusan National University-Institutional Animal Care and Use Committee (Miryang, South Korea; Approval Number PNU-2014-0572). Adult male and female SD rats (age, 8 weeks; weight, 220-250 g; n=6) purchased from Samtako Inc. (Osan, South Korea) were handled in the Pusan National University-Laboratory Animal Resources Center accredited by the Ministry of Food and Drug Safety (Osong, South Korea; Accredited Unit Number-000231) and the Association for Assessment and Accreditation of Laboratory Animal Care International (Frederick, MD, USA; Accredited Unit Number; 001525). Animals were provided with *ad libitum* access to water and a standard irradiated chow diet (Samtako Inc.) consisting of moisture (12.5%), crude protein (25.43%), crude fat (6.06%), crude fiber (3.9%), crude ash (5.31%), calcium (1.14%) and phosphorus (0.99%), throughout the feeding study. During the experiment, all rats were maintained in specific pathogen-free conditions under a

12-h light/dark cycle at 23±2°C and 50±10% relative humidity. Infant rats (age, 3 days) were obtained by breeding male and female SD rats.

Preparation of pRISMCs. pRISMCs were prepared as previously described (20), with slight modifications to the treatment duration and enzyme concentrations. The cells were collected from infant rather than adult rats, since the infant tissue had greater differentiation and proliferation abilities, similar to those of the fetus (20,21). Briefly, 3-day-old rats (n=5) were euthanized using a CO₂ chamber, following which their intestines were collected (Fig. 1A). The small intestines from 1 cm below the pyloric ring to the cecum were removed and opened along the mesenteric border (Fig. 1B). Luminal contents were then removed by washing with calcium-free Hank's solution [5.36 mmol/l KCl, 125 mmol/l NaCl, 0.34 mmol/l NaOH, 0.44 mmol/l Na₂HCO₃, 10 mmol/l glucose, 2.9 mmol/l sucrose and 11 mmol/l HEPES (pH 7.4)]. Tissues were pinned to the base of a silicon-covered Petri dish, following which the mucosa layers were removed by sharp dissection (Fig. 1C and D). Small tissue strips of the intestinal muscle (consisting of circular and longitudinal muscles) were incubated in digestion solution [1 mg/ml collagenase (catalog no. 4174; Worthington Biochemical Corporation, Lakewood, NJ, USA), 0.5 mg/ml trypsin inhibitor (catalog no. T9128; Sigma-Aldrich, St. Louis, MO, USA), 1 mg/ml bovine serum albumin (catalog no. A2153; Sigma-Aldrich)] at 37°C for 30 min (Fig. 1E). Following centrifugation at 1,000 x g, 23-25°C for 10 min, pRISMCs were seeded into culture plates containing Dulbecco's modified Eagle's medium (DMEM; HyClone; GE Healthcare Life Sciences, Logan, UT, USA) and grown in a 37°C humidified incubator under 5% CO₂ (Fig. 1F). pRISMCs were limited to passage 5 for cell culture studies to avoid significant genetic drift.

Contamination of the pRISMC population was assessed by reverse transcription-polymerase chain reaction (RT-PCR) analysis, performed as described previously (22) with slight modifications to the total RNA concentration. Total RNA was purified by removing media from pRISMCs and homogenizing the cells in RNazol (Tel-Test Inc., Friendswood, TX, USA). The isolated RNA was then measured by UV spectroscopy and 5 µg total RNA was used to synthesize cDNA. Oligo dT primers (500 ng; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) were annealed at 70°C for 10 min, and deoxyadenosine, deoxycytidine, deoxyguanosine and deoxythymidine triphosphates were added with 200 units of 200 U/µl Superscript II reverse transcriptase (catalog no. 18064-014; Invitrogen; Thermo Fisher Scientific, Inc.). Subsequently, 10 pmol sense and antisense primers (Macrogen, Inc., Seoul, Korea) were added, and the reaction mixture was subjected to 25 cycles of amplification using a PCR Core kit (Roche Diagnostics, Basel, Switzerland). Amplification was conducted in a Perkin-Elmer Thermal Cycler using the following cycling conditions: An initial denaturation step of 7 min at 94°C was performed, followed by 25 cycles of 30 sec at 94°C, 30 sec at 62°C and 45 sec at 72°C, and a final extension step of 7 min at 72°C. The primer sequences for target gene expression identification were as follows: Sense, 5'-GCCTG CCGAA ATGTA TGACG-3' and antisense, 5'-GGTTC TCTGG GTTGG GGT-3' for c-kit (an interstitial cell of cajal

marker); sense, 5'-TACTT CATGA AGCAG ACCAT CG-3' and antisense, 5'-CTGCA GCAGA GAGTC CTCTG AACTG-3' for protein gene product 9.5 (PGP9.5; a neuronal cell marker); sense, 5'-GCAAC TGAGC AATGA GCTGG TCAC-3' and antisense, 5'-CTGCT CTTG TACTG CTCCA CCATC-3' for myosin, heavy chain 11 (Myh11; a myosin-smooth muscle cell marker); and sense, 5'-TGG AAT CCT GTG GCA TCC ATG AAA C-3' and antisense, 5'-TAA AAC GCA GCT CAG TAA CAG TCC G-3' for β -actin. The experiment was repeated three times and all samples were analyzed in triplicate. The final PCR products were separated on a 1.2% agarose gel and were visualized by ethidium bromide staining. Of the three markers, only high expression levels of Myh11 were detected (Fig. 1G).

Preparation of five candidates. As listed in Table I, five laxative candidates (DG, 5-HMF, AD, HPC, UD) were selected from various compounds and substances derived from the roots of *L. platyphylla* as previously described (23-30). Candidates were selected according to the following criteria: i) Compounds and substances associated with the metabolic function of the intestines; ii) compounds and substances that stimulate intestinal cells; and iii) compounds and substances that have similar structures to laxative materials reported in previous studies (23-30). The root samples of *L. platyphylla* were collected from plantations in the Miryang area of South Korea between 2009 and 2010, and were identified by Dr Cha Shin Woo at the Herbal Crop Research Division, National Institute of Horticultural & Herbal Science (Eumseong, South Korea). Voucher specimens (ref. WPC-11-010) were deposited at the Functional Materials Bank of the Wellbeing RIS Center of Pusan National University. DG, 5-HMF, AD, HPC and UD were purchased from Sigma-Aldrich, whereas two commercial drugs, prucalopride (PCP; Resolor) and bisacodyl mixture (BS; Bicogreen), were acquired from Janssen Korea Ltd. (Seoul, South Korea) and Kolon Pharmaceuticals, Inc. (Gwachon, South Korea), respectively.

The roots of *L. platyphylla* were weighed and then ground with a Hanil mixer (HMF-3100S; Hanil Electronics Co., Ltd., Seoul, South Korea). *L. platyphylla* powder (~1 g) was sonicated in 10 ml distilled water for 1 h, followed by centrifugation for 10 min at 2,500 x g, 23-25°C. The supernatant was transferred to a 30 ml volumetric flask. This procedure was repeated three times and respective supernatants were combined. The final volume was adjusted to 30 ml with distilled water. Prior to use all samples were filtered through 0.45- μ m nylon membrane filters.

High performance liquid chromatography (HPLC) analysis. The one-dimensional HPLC system (Agilent 1100; Agilent Technologies, Inc., Santa Clara, CA, USA) consisted of a quaternary pump, an auto-sampler, a degasser, an automatic thermostatic column compartment and a diode array detector. Chromatographic conditions for AD, HPC and UD analysis were as follows: A Phenomenex Luna C18 column (150x4.6 mm internal diameter; 5 mm particle size; Phenomenex, Torrance, CA, USA) was used; gradient elution was performed with (A) 0.025% formic acid in water and (B) acetonitrile (0-10 min, 0-5% B; 10-20 min, 5% B; 20-30 min, 5-15% B; 30-40 min, 15% B; 40-50 min, 15-100% B; 50-55 min, 100% B; and

Table I. Candidates derived from *L. platyphylla* to investigate the laxative effects on the 5-hydroxytryptamine receptor signaling pathway.

Candidate	Medicinal effect (ref.)
Diosgenin	Anti-diabetic effect (21) Anti-allergic effect (22) Anti-inflammatory effect (23)
5-Hydroxymethylfurfural	Wound healing effect (24)
Adenosine	Improves hemolytic disease (25) Improves hematopoietic malignancy (26)
Hydroxypropyl cellulose	Improves cholesterol concentration (27)
Uridine	Sterol-lowering effect (28)

55-60 min, 100-0% B); the flow rate was 0.5 ml/min; and the column temperature was 30°C. For DD and 5-HMF analysis, gradient elution was performed with (A) deionized water and (B) acetonitrile (0-25 min, 30-90% B; and 25-40 min, 90% B). A flow rate of 1.0 ml/min was used. The flow rate and pressure were maintained at 1.53 ml/min and 35 \pm 2 psi, respectively. The wavelength was set at 254 nm and the output signal of the detector was recorded using Clarity™ Chromatography Software version 6.0 (DataApex, Prague, Czech Republic).

Determination of UD and AD concentration. Individual stock solutions of UD and AD were prepared at a concentration of 0.5 mg ml⁻¹ in distilled water. The quantification was performed using seven levels of external standards. The ranges obtained were 0.5-50 μ g ml⁻¹ depending on the concentration of each stock solution. Table II presents the calibration data and calculated limit of detection. The linearity of the method was evaluated by analyzing a series of standard UD and AD. Each of the six working UD and AD solutions (10 μ l) containing 0.5-50 μ g was subjected to HPLC. The elution was performed as previously described and standard calibration curves were obtained by plotting the concentration of UD and AD vs. peak area. The calibration range was chosen to reflect UD and AD concentrations in watermelon samples. The range included concentrations from the lower limit of detection (LOD) and limit of quantification (LOQ).

Treatment schedule. IEC-18, an epithelial cell line derived from the ileum of rat intestines, and B35, a neuroblastoma cell line derived from tumors of the neonatal rat CNS, were purchased from the Korean Cell Line Bank (Seoul, South Korea). The cells were cultured in a humidified incubator at 37°C under 5% CO₂ in Eagle's minimal essential medium with Earle's balanced salt solution (MEM/EBSS; catalog no. SH30024.01; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 2 mM glutamine, 100 U/ml penicillin and 100 μ g/ml streptomycin.

To prepare the total cell lysate, the three cell types were seeded at a density of 1x10⁷ cells/10 ml in 100-mm diameter culture dishes, and cultured with 20 μ M Lop (Sigma-Aldrich)




Figure 1. Preparation of pRISMCs from infant SD rats. (A) Intestine samples were collected from 3-day-old SD rats. (B) Small intestines were opened along the mesenteric border. (C) Mucosa layers were removed by sharp dissection, (D) leaving intestinal muscle. (E) Small tissue strips of the intestine muscle were harvested and then incubated in digestion solution with collagenase type 1. (F) pRISMCs were seeded into cell culture plates and their morphology was observed under an inverted microscope. Magnification, $\times 200$. (G) RT-PCR analysis of pRISMCs. The mRNA expression levels of c-kit, PGP9.5 and Myh11 were examined by RT-PCR in pRISMCs collected from infant intestines. pRISMCs, primary rat intestine smooth muscle cells; SD, Sprague Dawley; RT-PCR, reverse transcription-polymerase chain reaction; PGP9.5, protein gene product 9.5; Myh11, myosin, heavy chain 11.

for 12 h in a 37°C incubator. The Lop-containing culture media was then removed, and cells of each group were treated with 25 μM DG, 100 μM 5-HMF, 100 μM AD, 100 μM UD, 100 $\mu\text{g}/\text{ml}$ of HPC, 100 $\mu\text{g}/\text{ml}$ of AEtLP, 1 $\mu\text{g}/\text{ml}$ of PCP or 5 $\mu\text{g}/\text{ml}$ BS, whereas the vehicle control group received the same volume of dH_2O , for a further 12 h. The untreated group did not receive any treatment during the experimental period. Subsequently, cells harvested from 100-mm diameter culture dishes were homogenized with 1% Nonidet P-40 in 150 mM NaCl, 10 mM Tris HCl (pH 7.5) and 1 mM EDTA, then supplemented with a protein inhibitor mixture (Roche Diagnostics, Basel, Switzerland). Lysates were stored at -70°C until use.

Western blot analysis. Total proteins were extracted from pRISMC, IEC-18 and B35 cells treated with the five candidates using Pro-Prep Protein Extraction Solution (Intron Biotechnology, Inc., Seongnam, Korea). Following centrifugation at 11,000 $\times g$, 4°C for 5 min, the protein concentrations were

determined using a SMART™ Bicinchoninic Acid Protein assay kit (Thermo Fisher Scientific, Inc.). Proteins (30 μg) were separated by 4-20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis for 3 h, following which the resolved proteins were transferred to nitrocellulose membranes for 2 h at 40 V. Membranes were blocked with 10% skim milk in phosphate-buffered saline (PBS) for 1 h, and incubated with the primary antibodies, rabbit anti-G protein α subunit (1:1,000; catalog no. ab58916; G α ; Abcam, Cambridge, UK), rabbit anti-protein kinase C (1:1,000; catalog no. 2056; PKC; Cell Signaling Technology Inc., Danvers, MA, USA), rabbit anti-phosphorylated PKC (1:1,000; catalog no. 9371; p-PKC; Cell Signaling Technology Inc.) and rabbit anti- β -actin (1:2,000; catalog no. A2066; Sigma-Aldrich) overnight at 4°C. Membranes were washed with washing buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na_2HPO_4 , 2 mM KH_2PO_4 and 0.05% Tween 20) and incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (1:1,000; catalog no. 81-6120; Thermo Fisher Scientific, Inc.) at room temperature for 2 h.




Figure 2. Structural formula and chromatograms of the five candidates. Chromatograms of the five candidates were obtained by performing high performance liquid chromatography on the extracts of *L. platyphylla*. The peaks corresponding to each candidate are labeled. Peak height/area reflect the concentration of the candidates in the sample. DG, diosgenin; 5-HMF, 5-hydroxymethylfurfural; AD, adenosine; HPC, hydroxypropyl cellulose; UD, uridine.

Finally, the blots were developed using Chemiluminescence Reagent Plus kit (Pfizer Inc., Gladstone, NJ, USA). The signal image for each protein was acquired using the digital camera (1.92 MP resolution) of the FluorChem[®] FC2 Imaging system (Alpha Innotech Corporation, San Leandro, CA, USA) and their density was semi-quantified using AlphaView Program version 3.2.2 (Cell Biosciences, Inc., Santa Clara, CA). Total protein levels of three samples from each group were analyzed in three separate western blot analyses.

Analysis of inositol triphosphate (IP3) concentration. The concentration of IP3 in the three cell types was determined using a rat IP3 enzyme-linked immunosorbent assay kit (Cusabio Biotech Co., Ltd., Wuhan, China) according to the manufacturer's protocol. Following treatment with the five candidates, cells (2×10^7) were harvested and homogenized in ice-cold phosphate-buffered saline (pH 7.2-7.4) with a glass homogenizer (Sigma-Aldrich). Total cell lysates were prepared with a glass homogenizer and PBS, and centrifuged at $5,000 \times g$ for 5 min at room temperature, following which the supernatant was collected for analysis. An anti-IP3 detection antibody was added and samples were incubated at 37°C

for 60 min, followed by the addition of substrate solution for 15 min at 37°C . The reaction was terminated by the addition of stop solution and the plates were read at an absorbance of 450 nm using a VersaMax Plate reader (Molecular Devices, LLC, Sunnyvale, CA, USA).

Statistical analysis. Statistical analyses were performed using SPSS software version 10.10 (SPSS, Inc. Chicago, IL, USA). One-way analysis of variance, followed by Tukey's *post hoc* test, was performed to identify significant differences between the vehicle and candidate-treated groups, or between the untreated and Lop-treated groups. All values are presented as the mean \pm standard deviation. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

Identification of five candidates in *L. platyphylla*. The presence of the five candidates in *L. platyphylla* was confirmed using HPLC analysis. As presented in Fig. 2, DG, 5-HMF, AD, HPC and UD were detected in the HPLC chromatogram of *L. platyphylla* under the optimal conditions, although their




Figure 3. Alteration of Gα expression and PKC phosphorylation levels in pRISMC. (A) Western blot analysis was performed on total protein extracted from Lop-pretreated pRISMCs following treatment with the five laxative candidates. The levels of Gα expression and PKC phosphorylation were detected using specific antibodies. The β-actin protein expression level served as an endogenous control. The band intensity of the three proteins was determined by densitometry and the level of (B) Gα expression and (C) PKC phosphorylation was calculated relative to β-actin. Data are presented as the mean ± standard deviation of three replicates. *P<0.05 vs. untreated group; †P<0.05 vs. Lop+vehicle treatment group. Gα, G protein α; PKC, protein kinase C; pRISMCs, primary rat intestine smooth muscle cells; Lop, loperamide; No, untreated; Veh, vehicle; AEtLP, aqueous extract of *Liriope platyphylla*; DG, diosgenin; 5-HMF, 5-hydroxymethylfurfural; AD, adenosine; HPC, hydroxypropyl cellulose; UD, uridine; PCP, prucalopride; BS, bisacodyl.

concentrations and detection times varied. Of the candidates, HPC had the highest peak, and UD the lowest.

Effects of the five laxative candidates on the 5-HT receptor signaling pathway in intestinal muscle cells. To examine the effects of the five laxative candidates on the 5-HT receptor signaling pathway, the expression levels of Gα and the phosphorylation levels of PKC were measured in Lop-pretreated pRISMCs following treatment with the five laxative candidates (Fig. 3A). The protein expression levels of Gα were 140% greater in the Lop+vehicle group compared with the untreated group. However, Gα protein expression levels decreased to varying extents in the majority of treatment groups. Similar levels were detected in the Lop+AEtLP and Lop+PCP treatment groups, which were used as positive controls, whereas the lowest expression levels of Gα were measured in the Lop+5-HMF treatment group (Fig. 3B). The phosphorylation levels of PKC differed from

Gα expression levels. Phosphorylation levels were 430% greater in the Lop+vehicle treatment group compared with the untreated group. However, levels were rapidly recovered in the positive control Lop+AEtLP, Lop+PCP and Lop+BS treatment groups. Furthermore, a marked decrease in PKC phosphorylation was observed in the Lop+DG and Lop+AD treatment groups, whereas partial recovery was observed in the Lop+5-HMF treatment group. However, the level of PKC protein phosphorylation was not decreased in the Lop+HPC and Lop+UD treatment groups (Fig. 3C). Taken together, these results suggest that DG, 5-HMF and AD may stimulate the complete or partial recovery of Gα expression and PKC phosphorylation levels induced by Lop treatment in smooth muscle cells of rat intestine.

Effects of the five laxative candidates on the 5-HT receptor signaling pathway in epithelial cells. To determine whether the effect on the 5-HT receptor signaling pathway observed in




Figure 4. Alteration of G α expression and PKC phosphorylation levels in IEC-18 cells. (A) Western blot analysis was performed on total protein extracted from the Lop-pretreated IEC-18 cells following treatment with the five laxative candidates. The levels of G α expression and PKC phosphorylation were detected with specific antibodies. The β -actin protein expression level served as an endogenous control. The band intensity of the three proteins was determined by densitometry and the level of (B) G α expression and (C) PKC phosphorylation was calculated relative to β -actin. Data are presented as the mean \pm standard deviation of three replicates. ^aP<0.05 vs. untreated group; ^bP<0.05 vs. Lop+vehicle treatment group. G α , G protein α ; PKC, protein kinase C; IEC-18, intestinal epithelial cells 18; Lop, loperamide; No, untreated; Veh, vehicle; AEtLP, aqueous extract of *Liriope platyphylla*; DG, diosgenin; 5-HMF, 5-hydroxymethylfurfural; AD, adenosine; HPC, hydroxypropyl cellulose; UD, uridine; PCP, prucalopride; BS, bisacodyl.

pRISMCs occurred in epithelial cells, the previous experiment was repeated in IEC-18 cells (Fig. 4A). Increased G α expression levels (75%) were detected in the Lop+vehicle treatment group compared with the untreated group (Fig. 4B). In the Lop+AEtLP and Lop+PCP groups, this level increased by 12.6 and 8% compared with the Lop+vehicle treatment group. A significant decrease (P=0.042) was detected only following treatment with three (DG, 5-HMF and UD) out of the five candidates.

The phosphorylation levels of PKC differed from G α expression levels (Fig. 4C). Phosphorylation levels increased 358% in the Lop+vehicle treatment group compared with the untreated group. However, Lop+AEtLP and Lop+BS treatment induced complete recovery of PKC phosphorylation levels, whereas Lop+PCP treatment induced a significant decrease of 56.4% (P=0.016). Taken together, these results indicate that all five candidates may mimic the effects of AEtLP and BS in intestinal epithelial cells.

Effect of the five laxative candidates on the 5-HT receptor signaling pathway in neuronal cells. To determine whether the five laxative candidates affect the 5-HT receptor signaling pathway in neuronal cells, the expression levels of G α and phosphorylation levels of PKC were measured in Lop-pretreated B35 cells following treatment with the five laxative candidates (Fig. 5A). The G α expression levels were reduced by 49% in the Lop+vehicle treatment group compared with the untreated group (Fig. 5B). These levels were further decreased by 83-95% in the Lop+AEtLP, Lop+PCP and Lop+BS positive control treatment groups. Following treatment with the five candidates, the expression levels of G α increased in the Lop+5-HMF and Lop+HPC treatment groups compared with the Lop+vehicle treatment group. The G α expression levels remained constant in the three remaining groups (DG, AD and UD). PKC phosphorylation levels did not correspond with G α expression levels (Fig. 5C). Phosphorylation levels were not altered in the




Figure 5. Alteration of G α expression and PKC phosphorylation levels in B35 cells. (A) Western blot analysis was performed on total protein extracted from the Lop-pretreated B35 cells following treatment with the five laxative candidates. The levels of G α expression and PKC phosphorylation were detected with specific antibodies. The β -actin protein expression level served as an endogenous control. The band intensity of the three proteins was determined using densitometry and the level of (B) G α expression and (C) PKC phosphorylation was calculated relative to β -actin. Data are presented as the mean \pm standard deviation of three replicates. ^aP<0.05 vs. untreated group; ^bP<0.05 vs. Lop+vehicle treatment group. G α , G protein α ; PKC, protein kinase C; Lop, loperamide; No, untreated; Veh, vehicle; AEtLP, aqueous extract of *Liriope platyphylla*; DG, diosgenin; 5-HMF, 5-hydroxymethylfurfural; AD, adenosine; HPC, hydroxypropyl cellulose; UD, uridine; PCP, prucalopride; BS, bisacodyl.

Lop+vehicle and Lop+AEtLP treatment groups; however, they were increased by 120% in the Lop+PCP and BS treatment groups. The Lop+UD treatment group also exhibited increased PKC phosphorylation levels; however, a significant decrease ($P=0.032$) was detected in the DG, 5-HMF and AD treatment groups. Taken together, the above results indicated that only UD may mimic the effect of PCP and BS on PKC phosphorylation levels in B35 neuroblastoma cells.

Effects of the five laxative candidates on IP₃ concentration. IP₃ concentrations in pRISMCs, IEC-18 and B35 cells co-treated with Lop and the five candidates were examined to confirm the results of the 5-HT receptor signaling pathway analysis. Although IP₃ was detected in pRISMCs, IEC-18 and B35 cells, a significant alteration ($P=0.017$) during Lop treatment was detected only in pRISMCs (Fig. 6A). IEC-18 (Fig. 6B) and B35 (Fig. 6C) cells did not exhibit any significant alterations ($P=0.028$) in IP₃ concentrations. In pRISMCs, the relative levels of IP₃ were decreased by 21% in the Lop+vehicle treatment group compared with the untreated group. However, these

levels recovered following AEtLP, PCP and BS treatment. In addition, IP₃ levels were increased in all five candidate-treated groups, although to a lesser extent than AEtLP and PCP. The greatest increase (223%) was detected in the Lop+UD treatment group. These results demonstrate that UD induces a marked increase of IP₃ concentration in smooth muscle cells.

Quantification of AD and UD. UD was selected as the candidate with the greatest potential as a novel laxative based on the G α expression, PKC phosphorylation and IP₃ concentration levels data; therefore, the concentration of UD was quantified. In addition, AD was quantified as a control. The linearity for AD and UD analysis was assessed using six standard solutions (each injected in triplicate) in a 0.5–50.0 $\mu\text{g ml}^{-1}$ concentration range. The six-point calibration curves were observed to be linear as least squares regression gave a correlation coefficient of 0.9999 (Table II). LOD and LOQ were defined as a signal-to-noise ratio of 3 and 10, respectively; LOD ranged from 0.205 to 0.738 $\mu\text{g ml}^{-1}$ and LOQ from 0.062 to 0.224 $\mu\text{g ml}^{-1}$. Comparing retention times with

Table II. Contents of AD and UD in roots sample of *L. platyphylla*.

Compound	Regression equation	Correlation coefficient	Linear range ($\mu\text{g/l}$)	Limit of detection ($\mu\text{g/l}$)	Limit of quantification ($\mu\text{g/l}$)	Content ($\mu\text{g/g}$ dry weight)
AD	$y=33.02x-2.35$	0.999994	0.5-50.0	0.224	0.738	78 ± 2
UD	$y=23.79x+0.34$	0.999999	0.5-50.0	0.062	0.205	172 ± 2

AD, adenosine; UD, uridine.




Figure 6. Alteration of IP3 concentration in pRISMCs, IEC-18 and B35 cells. Following treatment with Lop for 12 h, the three cell types were incubated with the five candidates. The IP3 concentration in the total cell lysate of (A) pRISMCs, (B) IEC-18 and (C) B35 cells was measured using an enzyme-linked immunosorbent assay kit that detected 5 to 1000 pg/ml IP3. Data are presented as the mean \pm standard deviation of three replicates. ^aP<0.05 vs. untreated group; ^bP<0.05 vs. Lop+vehicle treatment group. IP3, inositol triphosphate; pRISMC, primary rat intestine smooth muscle cells; IEC-18, intestinal epithelial cells 18; Lop, loperamide; No, untreated; Veh, vehicle; AEtLP, aqueous extract of *Liriope platyphylla*; DG, diosgenin; 5-HMF, 5-hydroxymethylfurfural; AD, adenosine; HPC, hydroxypropyl cellulose; UD, uridine; PCP, prucalopride; BS, bisacodyl.

those of authentic standards, UD and AD were revealed to be 172 and 78 $\mu\text{g/g}$ dry weight, respectively (Table II).

Discussion

Constipation is a heterogeneous disease associated with several symptoms, including infrequent bowel movements, difficult fecal passage and a sensation of incomplete defecation (31,32). In accordance with an increase in the incidence of constipation, attempts have been made to identify novel drugs from various natural resources. In an effort to purify and examine novel drugs for the treatment of constipation, the effects of five laxative candidates originating from *L. platyphylla* were examined in three major cell types present in the transverse colon. The results of the present study demonstrated the potential of UD to mimic the effects of PCP and AEtLP in pRISMCs, ICE-180 and B35 cells, although animal studies are

necessary to clarify the laxative effects on chronic constipation. The present study investigated $G\alpha$, PKC and IP3 within the downstream signaling pathway of the 5-HT receptor as their regulation may closely associate with movement through the gastrointestinal tract.

DG is a steroid saponin produced by saponin hydrolysis during treatment with acids, strong bases or enzymes (33). In addition, DG may be extracted from the tubers of *Dioscorea esculenta*, *Angelica gigas* and *Trigonella foenum-graecum* (34), and exerts biological activity against various metabolic diseases, including dyslipidemia, obesity, diabetes, cholestasis and cancer (33,35). A limited number of studies have been conducted to investigate the effects of DG on PKC activation in the 5-HT receptor signaling pathway; however, a previous study revealed significantly increased PKC phosphorylation induced by DG administration in type I diabetic rats (35). In the present study, the phosphorylation levels of PKC were

decreased in smooth muscle cells, epithelial cells and neuronal cells following Lop + DG treatment. These differences may be due to various factors, including Lop cotreatment and experimental conditions.

Extracellular nucleotide triphosphates (NTPs), including adenosine triphosphate (ATP) and uridine triphosphate (UTP), regulate various physiological actions in numerous tissues and cell types (36). In the airways of the lung, these compounds activate Cl⁻ secretion from cystic fibrosis (CF) and non-CF airway epithelia, and regulate goblet cell-mediated mucin release (37,38). This process is mediated by P2Y or P2 U receptors, which are G protein-coupled receptors that activate the phospholipase C (PLC) signaling cascade (39,40). PLC results in calcium release, PKC activation and phosphatidylinositol 4,5-bisphosphate depletion through cleavage into diacylglycerol and IP₃ (40). Although numerous studies have reported the function of extracellular NTPs as regulatory molecules, their role in the 5-HT receptor signaling pathway associated with constipation has not been investigated. However, it has previously been suggested that ATP and UTP are associated with the improvement of constipation since their activity stimulates mucin release from goblet cells (38). In the present study, AD in muscle cells and epithelial cells induced effects on PKC phosphorylation that mimicked PCP and BS, while UD was effective in epithelial cells and neuronal cells. These results provide the first evidence that AD and UD may improve Lop-induced constipation via regulation of the 5-HT receptor signaling pathway.

Of the various insoluble dietary fibers, including psyllium, glucomannan and chitosan, cellulose facilitates the movement of waste through the human digestive tract and prevents chronic constipation (41). Oral administration of 5 mg/day cellulose significantly increased fecal excretion in Lop-induced constipated rats (41), whereas methylcellulose treatment increased the frequency of bowel movements and the ease of fecal passage (42). To the best of our knowledge, no studies have reported an association between HPC and chronic constipation, although it is widely used to treat insufficient tear production, and as food additives and disintegrants. In the present study, the effect of HPC treatment on G α expression and PKC phosphorylation levels was examined in three cell types present in the transverse colon, and the results revealed that HPC mimicked the effect of AEtLP on G α expression in pRISMCs and IEC-18 as well as PKC phosphorylation in IEC-18 and B35 cells.

In conclusion, the present study investigated the effects of five laxative candidates derived from *L. platyphylla* on the 5-HT receptor signaling pathway to select a potential novel laxative. Laxative candidates were selected on the basis of reversing the effects of Lop and mimicking the activity of current therapeutic agents or AEtLP in at least two cell types. Analysis of the G α expression levels in the three cell types revealed three laxative candidates (DG, 5-HMF and UD), whereas results from PKC phosphorylation in the three cell types suggested three laxative candidates (DG, AD and UD). The additional analysis of IP₃ concentration indicated only one strong candidate (UD). Therefore, the results of the present study suggested that UD may be considered as a potential laxative in the treatment of chronic constipation, although it did

not exactly mimic the effects of AEtLP, PCP and BS. Further studies are required to investigate the therapeutic effects of these laxatives in a Lop-induced constipation model based on the measurement of the number of feces, histological analysis and the expression of associated proteins.

Acknowledgements

The authors would like to thank Miss. Jin Hyang Hwang, the animal technician, for directing the Animal Facility and Care at the Laboratory Animal Resources Center of Pusan National University (Miryang, Korea), and Professor Byung Joo Kim (Pusan National University School of Korean Medicine, Yangsan, Korea) for technical support in the collection of primary smooth muscle cells from the rat intestines. The present study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (grant no. 2014R1A1A2058360).

References

1. Young SN: How to increase serotonin in the human brain without drugs. *J Psychiatry Neurosci* 32: 394-399, 2007.
2. Ahn J and Ehrenpreis ED: Emerging treatments for irritable bowel syndrome. *Expert Opin pharmacother* 3: 9-21, 2002.
3. Bulbring E and Crema A: The release of 5-hydroxytryptamine in relation to pressure exerted on the intestinal mucosa. *J Physiol* 146: 18-28, 1959.
4. Gershon MD: Serotonin: Its role and receptors in enteric neurotransmission. *Adv Exp Med Biol* 294: 221-230, 1991.
5. Baker DE: Rationale for using serotonergic agents to treat irritable bowel syndrome. *Am J Health Syst Pharm* 62: 700-711; quiz 712-713, 2005.
6. Sikander A, Rana SV and Prasad KK: Role of serotonin in gastrointestinal motility and irritable bowel syndrome. *Clin Chim Acta* 403: 47-55, 2009.
7. Costedio MM, Hyman N and Mawe GM: Serotonin and its role in colonic function and in gastrointestinal disorders. *Dis Colon Rectum* 50: 376-388, 2007.
8. Crowell MD: Role of serotonin in the pathophysiology of the irritable bowel syndrome. *Br J Pharmacol* 141: 1285-1293, 2004.
9. El-Salhy M, Danielsson A, Stenling R and Grimelius L: Colonic endocrine cells in inflammatory bowel disease. *J Intern Med* 242: 413-419, 1997.
10. Lincoln J, Crowe R, Kamm MA, Burnstock G and Lennard-Jones JE: Serotonin and 5-hydroxyindol acetic acid are increased in the sigmoid colon in severe idiopathic constipation. *Gastroenterol* 98: 1219-1225, 1990.
11. Zhao R, Baig MK, Wexner SD, Chen W, Singh JJ, Nogueras JJ and Woodhouse S: Enterochromaffin and serotonin cells are abnormal for patients with colonic inertia. *Dis Colon Rectum* 43: 858-863, 2000.
12. Callahan MJ: Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. *J Clin Gastroenterol* 35 (1 Suppl): S58-S67, 2002.
13. Kamm MA, Müller-Lissner S, Talley NJ, Tack J, Boeckxstaens G, Minushkin ON, Kalinin A, Dzieniszewski J, Haecck P, Fordham F, *et al.*: Tegaserod for the treatment of chronic constipation: A randomized, double-blind, placebo-controlled multinational study. *Am J Gastroenterol* 100: 362-372, 2005.
14. von der Ohe MR, Hanson RB and Camilleri M: Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. *Gut* 35: 536-541, 1994.
15. Kakino M, Izuta H, Ito T, Tsuruma K, Araki Y, Shimazawa M, Oyama M, Iinuma M and Hara H: Agarwood induced laxative effects via acetylcholine receptors on loperamide-induced constipation in mice. *Biosci Biotechnol Biochem* 74: 1550-1555, 2010.
16. Lee HY, Kim JH, Jeung HW, Lee CU, Kim DS, Li B, Lee GH, Sung MS, Ha KC, Back HI, *et al.*: Effects of *Ficus carica* paste on loperamide-induced constipation in rats. *Food Chem Toxicol* 50: 895-902, 2012.

17. Méité S, Bahi C, Yéo D, Datté JY, Djaman JA and N'guessan DJ: Laxative activities of *Mareya micrantha* (Benth.) Müll. Arg. (Euphorbiaceae) leaf aqueous extract in rats. *BMC Complement Altern Med* 10: 7, 2010.
18. Wintola OA, Sunmonu TO and Afolayan AJ: The effect of *Aloe ferox* Mill. in the treatment of loperamide-induced constipation in Wistar rats. *BMC Gastroenterol* 10: 95, 2010.
19. Kim JE, Lee YJ, Kwak MH, Ko J, Hong JT and Hwang DY: Aqueous extracts of *Liriope platyphylla* induced significant laxative effects on loperamide-induced constipation of SD rats. *BMC Complement Altern Med* 13: 333, 2013.
20. Kim BJ: Shengmaisan refulates pacemaker potentials in interstitial cells of cajal in mice. *J Pharmacopuncture* 16: 36-42, 2013.
21. Thyberg J, Hedin U, Sjölund M, Palmberg L and Bottger BA: Regulation of differentiated properties and proliferation of arterial smooth muscle cells. *Arteriosclerosis* 10: 966-990, 1990.
22. Parajuli SP, Choi S, Lee J, Kim YD, Park CG, Kim MY, Kim HI, Yeum CH and Jun JY: The inhibitory effects of hydrogen sulfide on pacemaker activity of interstitial cells of cajal from mouse small intestine. *Korean J Physiol Pharmacol* 14: 83-89, 2010.
23. Pari L, Monisha P and Mohamed Jalaludeen A: Beneficial role of diosgenin on oxidative stress in aorta of streptozotocin induced diabetic rats. *Eur J Pharmacol* 691: 143-150, 2012.
24. Huang CH, Ku CY and Jan TR: Diosgenin attenuates allergen-induced intestinal inflammation and IgE production in a murine model of food allergy. *Planta Med* 75: 1300-1305, 2009.
25. Yamada T, Hoshino M, Hayakawa T, Ohhara H, Yamada H, Nakazawa T, Inagaki T, Iida M, Ogasawara T, Uchida A, *et al*: Dietary diosgenin attenuates subacute intestinal inflammation associated with indomethacin in rats. *Am J Physiol* 273: G355-G364, 1997.
26. Black CT, Hennessey PJ, Ford EG and Andrassy RJ: Protein glycosylation and collagen metabolism in normal and diabetic rats. *J Surg Res* 47: 200-202, 1989.
27. Nicolau CT, Teitel P, Bratu V, Xenakis A and Butoianu E: Favorable therapeutic effect of adenosine monophosphate (AMP) in a case of compensated chronic hemolytic disease due to insufficiency of erythrocytic energetic metabolism. *Med Interna (Bucur)* 17: 423-430, 1965 (In Romanian).
28. Tsukamoto H: Extracellular adenosine is a therapeutic target for limiting graft-versus-host disease and enhancing the graft-versus-tumor effect against hematopoietic malignancy. *Yakugaku Zasshi* 134: 1021-1027, 2014 (In Japanese).
29. Krishnaiah YS, Kumar MS, Raju V, Lakshmi M and Rama B: Penetration-enhancing effect of ethanolic solution of menthol on transdermal permeation of ondansetron hydrochloride across rat epidermis. *Drug Deliv* 15: 227-234, 2008.
30. Oswald S, Giessmann T, Luetjohann D, Wegner D, Roszkopf D, Weitschies W and Siegmund W: Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. *Clin Pharmacol Ther* 80: 477-485, 2006.
31. Herz MJ, Kahan E, Zalevski S, Aframian R, Kuznitz D and Reichman S: Constipation: A different entity for patients and doctors. *Fam Pract* 13: 156-159, 1996.
32. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ and Müller-Lissner SA: Functional bowel disorders and functional abdominal pain. *Gut* 45 (Suppl 2): II43-II47, 1999.
33. Raju J and Rao CV: Diosgenin, a steroid saponin constituent of Yams and Fenugreek: Emerging evidence for applications in medicine. In: *Bioactive Compounds in Phytomedicine*. Rasooli I (ed). InTech, Rijeka, pp125-142, 2012.
34. Taylor WG, Elder JL, Chang PR and Richards KW: Microdetermination of diosgenin from fenugreek (*Trigonella foenum-graecum*) seeds. *J Agric Food Chem* 48: 5206-5210, 2000.
35. Sato K, Fujita S and Iemitsu M: Acute administration of diosgenin or dioscorea improves hyperglycemia with increases muscular steroidogenesis in STZ-induced type 1 diabetic rats. *J Steroid Biochem Mol Biol* 143: 152-159, 2014.
36. Barke AJ and Julius D: Signaling by extracellular nucleotides. *Annu Rev Cell Dev Biol* 12: 519-541, 1996.
37. Knowler MR, Clarke LL and Boucher RC: Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. *N Engl J Med* 325: 533-538, 1991.
38. Lethem MI, Dowell ML, Van Scott M, Yankaskas JR, Egan T, Boucher RC and Davis CW: Nucleotide regulation of goblet cells in human airway epithelial explants: Normal exocytosis in cystic fibrosis. *Am J Respir Cell Mol Biol* 9: 315-322, 1993.
39. Ralevic V and Burnstock G: Receptors for purines and pyrimidines. *Pharmacol Rev* 50: 413-492, 1998.
40. Falkengurter BH, Dickson EJ and Hille B: Quantitative properties and receptor reserve of the DAG and PKC branch of G(q)-coupled receptor signaling. *J Gen Physiol* 141: 537-555, 2013.
41. Shimotoyodome A, Meguro S, Hase T, Tokimitsu I and Sakata T: Sulfated polysaccharides, but not cellulose, increase colonic mucus in rats with loperamide-induced constipation. *Dig Dis Sci* 46: 1482-1489, 2001.
42. Snape WJ Jr: The effect of methylcellulose on symptoms of constipation. *Clin Ther* 11: 572-579, 1989.